soul trial oral semaglutide cardiovascular outcomes results 2025 nejm 2024 Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results Semaglutide cardiovascular outcomes align more

GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)are used to manage type 2 diabetes and obesity in the UK

Reperfusion therapies, which have revolutionized the management of acute stroke cases, can restore blood flow

Adipose tissue functions as an active immunological organ in psoriasis, secreting pro-inflammatory adipokines (leptin, resistin, adiponectin dysregulation) and amplifying the IL-17/IL-23 and TNF- axes that drive skin disease

Metformin remains the first-line pharmacological treatment for glycaemic control in type 2 diabetes, following dietary and lifestyle advice